Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

539741

Sigma-Aldrich

PTP1B Inhibitor

PTP1B Inhibitor, CAS 765317-72-4, is a cell-permeable, selective, reversible and non-competitive allosteric inhibitor of PTP1B (IC₅₀ = 4 µM and 8 µM for PTP1B403 and PTP1B298, respectively).

Sinonimo/i:

PTP1B Inhibitor, 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide, PTP Inhibitor XXII

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

5 MG
CHF 276.00

CHF 276.00


Spedizione prevista il17 maggio 2025



Scegli un formato

Cambia visualizzazione
5 MG
CHF 276.00

About This Item

Formula empirica (notazione di Hill):
C26H19Br2N3O7S3
Numero CAS:
Peso molecolare:
741.45
Numero MDL:
Codice UNSPSC:
12352200
NACRES:
NA.77

CHF 276.00


Spedizione prevista il17 maggio 2025


Livello qualitativo

Saggio

≥95% (HPLC)

Stato

solid

Produttore/marchio commerciale

Calbiochem®

Condizioni di stoccaggio

OK to freeze
protect from light

Colore

white

Solubilità

DMSO: 100 mg/mL
ethanol: 5 mg/mL

Condizioni di spedizione

wet ice

Temperatura di conservazione

−20°C

Stringa SMILE

[S](=O)(=O)(Nc5[s]ccn5)c1ccc(cc1)N[S](=O)(=O)c2cc3[o]c(c(c3cc2)C(=O)c4cc(c(c(c4)Br)O)Br)CC

InChI

1S/C26H19Br2N3O7S3/c1-2-21-23(24(32)14-11-19(27)25(33)20(28)12-14)18-8-7-17(13-22(18)38-21)41(36,37)30-15-3-5-16(6-4-15)40(34,35)31-26-29-9-10-39-26/h3-13,30,33H,2H2,1H3,(H,29,31)
SXKBTDJJEQQEGE-UHFFFAOYSA-N

Descrizione generale

A cell-permeable, selective, reversible, and non-competitive allosteric inhibitor of PTP1B (IC50 = 4 µM and 8 µM for PTP1B403 and PTP1B298, respectively). Binds to a novel site away from the catalytic pocket and inhibits PTP1B activity by preventing closure of the WPD loop. Also available in InSolution format (Cat. No. 539749.

Azioni biochim/fisiol

Cell permeable: yes
Primary Target
PTP1B403
Product does not compete with ATP.
Reversible: yes
Target IC50: 4 µM and 8 µM for PTP1B403 and PTP1B298, respectively

Confezionamento

Packaged under inert gas

Attenzione

Toxicity: Standard Handling (A)

Ricostituzione

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Altre note

Wiesmann, C., et al. 2004. Nat. Struct. Mol. Biol.11, 730.

Note legali

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Vitor Ferreira et al.
Redox biology, 63, 102741-102741 (2023-05-26)
Olanzapine (OLA), a widely used second-generation antipsychotic (SGA), causes weight gain and metabolic alterations when administered orally to patients. Recently, we demonstrated that, contrarily to the oral treatment which induces weight gain, OLA administered via intraperitoneal (i.p.) in male mice
Sarah Zierold et al.
Journal of the American Heart Association, 10(6), e018322-e018322 (2021-03-06)
Background Brain-derived neurotrophic factor (BDNF) is expressed in neuronal and nonneuronal cells and may affect vascular functions via its receptor, tropomyosin-related kinase B (TrkB). In this study, we determined the expression of BDNF in different perivascular adipose tissue (PVAT) depots
Hyo Jeong Kim et al.
Frontiers in neuroscience, 15, 725398-725398 (2021-10-26)
Rett syndrome (RTT) is a severe X-linked dominant neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene; MeCP2 regulates the expression of brain-derived neurotrophic factor (BDNF) and increasing BDNF levels ameliorates RTT symptoms. However, the clinical application
Bo Gong et al.
Nature, 631(8020), 415-423 (2024-06-13)
Directed cell migration is driven by the front-back polarization of intracellular signalling1-3. Receptor tyrosine kinases and other inputs activate local signals that trigger membrane protrusions at the front2,4-6. Equally important is a long-range inhibitory mechanism that suppresses signalling at the

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.